Dtsch Med Wochenschr 2012; 137(50): 2643-2656
DOI: 10.1055/s-0032-1327225
CME | Review article
Gastroenterologie
© Georg Thieme Verlag KG Stuttgart · New York

Intestinale Motilitätsstörungen

Gastrointestinal dysfunction
J. Keller
1   Medizinische Klinik, Israelitisches Krankenhaus, Hamburg
› Author Affiliations
Further Information

Publication History

03 August 2012

22 November 2012

Publication Date:
05 December 2012 (online)

 
  • Literatur

  • 1 Camilleri M. Appraisal of medium- and long-term treatment of gastroparesis and chronic intestinal dysmotility. Am J Gastroenterol 1994; 89: 1769-1774
  • 2 Camilleri M, Kerstens R, Rykx A et al. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008; 358: 2344-2354
  • 3 Connor FL, Di Lorenzo C. Chronic intestinal pseudo-obstruction: assessment and management. Gastroenterology 2006; 130: 29-36
  • 4 De Giorgio R, Camilleri M. Human enteric neuropathies: morphology and molecular pathology. Neurogastroenterol Motil 2004; 16: 515-531
  • 5 Enck P, van der Voort I, Klosterhalfen S. Biofeedback therapy in fecal incontence and constipation. Neurogastroenterol Motil 2009; 21: 1133-1141
  • 6 Furness JB. The enteric nervous system: normal functions and enteric neuropathies. Neurogastroenterol Motil 2008; 20 (Suppl. 01) 32-38
  • 7 Glia A, Akerlund JE, Lindberg G. Outcome of colectomy for slow-transit constipation in relation to presence of small-bowel dysmotility. Dis Colon Rectum 2004; 47: 96-102
  • 8 Hyman PE. Adolescents and young adults with Hirschsprung's disease. Curr Gastroenterol Rep 2006; 8: 425-429
  • 9 Kamm MA, Dudding TC, Melenhorst J et al. Sacral nerve stimulation for intractable constipation. Gut 2010; 59: 333-340
  • 10 Keller J, Franke A, Storr M et al. Klinisch relevante Atemtests in der gastroenterologischen Diagnostik – Empfehlungen der Deutschen Gesellschaft für Neurogastroenterologie und Motilität sowie der Deutschen Gesellschaft für Verdauungs- und Stoffwechselerkrankungen. Z Gastroenterol 2005; 43: 1071-1090
  • 11 Keller J, Wedel T, Seidl H et al. S3-Leitlinie der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Neurogastroenterologie und Motilität (DGNM) zu Definition, Pathophysiologie, Diagnostik und Therapie intestinaler Motilitätsstörungen. Z Gastroenterol 2011; 49: 17
  • 12 Kessmann J. Hirschsprung's disease: diagnosis and management. Am Fam Physician 2006; 74: 1319-1322
  • 13 Knowles CH, De Giorgio R, Kapur RP et al. Gastrointestinal neuromuscular pathology: guidelines for histological techniques and reporting on behalf of the Gastro 2009 International Working Group. Acta neuropathologica 2009; 118: 271-301
  • 14 Knowles CH, De Giorgio R, Kapur RP et al. The London Classification of gastrointestinal neuromuscular pathology: report on behalf of the Gastro 2009 International Working Group. Gut 2010; 59: 882-887
  • 15 Koh CE, Young CJ, Young JM et al. Systematic review of randomized controlled trials of the effectiveness of biofeedback for pelvic floor dysfunction. Br J Surg 2008; 95: 1079-1087
  • 16 Layer P. Motilität. In: Ell C, Fischbach W, Layer P, eds, GastroUpdate 2011. Heidelberg, New York: Springer; 2011
  • 17 Lloyd DA, Gabe SM. Managing liver dysfunction in parenteral nutrition. Proc Nutr Soc 2007; 66: 530-538
  • 18 Mehendale SR, Yuan CS. Opioid-induced gastrointestinal dysfunction. Dig Dis 2006; 24: 105-112
  • 19 Miyamoto M, Egami K, Maeda S et al. Hirschsprung's disease in adults: report of a case and review of the literature. Journal of Nippon Medical School = Nihon Ika Daigaku zasshi 2005; 72: 113-120
  • 20 Mollenbrink M, Bruckschen E. [Treatment of chronic constipation with physiologic Escherichia coli bacteria. Results of a clinical study of the effectiveness and tolerance of microbiological therapy with the E. coli Nissle 1917 strain (Mutaflor)]. Med Klin (Munich) 1994; 89: 587-593
  • 21 Muller-Lissner S, Rykx A, Kerstens R et al. A double-blind, placebo-controlled study of prucalopride in elderly patients with chronic constipation. Neurogastroenterol Motil 2010; 22: 991-998, e255
  • 22 Panchal SJ, Muller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract 2007; 61: 1181-1187
  • 23 Ponec RJ, Saunders MD, Kimmey MB. Neostigmine for the treatment of acute colonic pseudo-obstruction. N Engl J Med 1999; 341: 137-141
  • 24 Quartero AO, Meineche-Schmidt V, Muris J et al. Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2005; DOI: DOI: 10.1002/14651858.CD003460.pub2. CD003460
  • 25 Ramkumar D, Rao SS. Efficacy and safety of traditional medical therapies for chronic constipation: systematic review. Am J Gastroenterol 2005; 100: 936-971
  • 26 Saunders MD. Acute colonic pseudo-obstruction. Best Pract Res Clin Gastroenterol 2007; 21: 671-687
  • 27 Saunders MD, Kimmey MB. Systematic review: acute colonic pseudo-obstruction. Aliment Pharmacol Ther 2005; 22: 917-925
  • 28 Seidl H, Pehl C, Schepp W et al. Chronisch intestinale Pseudoobstruktion – Übersicht und Update 2008. Z Gastroenterol 2008; 46: 704-711
  • 29 Stanghellini V, Cogliandro RF, de Giorgio R et al. Chronic intestinal pseudo-obstruction: manifestations, natural history and management. Neurogastroenterol Motil 2007; 19: 440-452
  • 30 Tack J, van Outryve M, Beyens G et al. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 2009; 58: 357-365
  • 31 Tuteja AK, Biskupiak J, Stoddard GJ et al. Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain. Neurogastroenterol Motil 2010; 22: 424-430, e496